Evolus

FDA Approves Jeuveau PrabotulinumtoxinA-xvfs

New Neurotoxin Enters Market

There is a new injectable neurotoxin coming to the aesthetics market. On February 1, the U.S. Food and Drug Administration approved Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) for temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. Jeuveau is a proprietary 900 kDa purified botulinum toxin type A formulation.

Evolus Expands Leadership Team

Evolus, a company dedicated to aesthetic medicine that is currently developing its own botulinum toxin injectable, has expanded its leadership team with the appointments of three key executives, who will report to President and CEO David Moatazedi. Kurt Knab is the vice president of sales, Alejandro “Alex” Sabad is vice president of operations and Amy Marinne Fox is vice president of human resources.

Silvernail Named CFO of Evolus

Evolus Prepares for Botulinum Toxin Launch

Lauren Silvernail, former chief financial officer (CFO) and chief business officer at Revance Therapeutics, is now the CFO and executive vice president of corporate development at Evolus. Prior to her time at Revance, Silvernail served as CFO and VP of corporate development at ISTA Pharmaceuticals. She joins the company as it works towards approval of its prabotulinumtoxinA injectable (DWP-450) for the treatment of moderate-to-severe glabellar lines.

Evolus Vows To Move Forward As FDA Fails To Approve Its Neurotoxin

The approval of Evolus’ DWP-450 (prabotulinumtoxinA) has hit a snag, reportedly due to issues at the appointed manufacturing facility. The U.S. Food & Drug Administration issued a complete response letter (CRL) to the company’s biologic license application for DWP-450 outlining concerns that must be addressed before the FDA can approve the new neurotoxin for marketing in the U.S.